QLT Reports Positive Results From Phase 1b Trial With QLT091001

(RTTNews) - QLT Inc. (QLTI) Friday reported positive data from its Phase 1b retreatment trial with oral synthetic Cis-Retinoid or QLT091001 in patients with Leber Congenital Amaurosis or LCA or Retinitis Pigmentosa or RP.

The results showed clinically significant improvements in visual fields with repeated dosing of QLT091001 in both LCA and RP patients with RPE65 or LRAT mutations. There was also a slight positive effect on visual acuity in both patient groups.

The Phase 1b retreatment trial was a multicenter, open-label extension study in which LCA or RP patients with RPE65 or LRAT mutations who had been treated with a single course of QLT091001 in the company's previously completed Phase 1b study, received up to three 7-day courses of QLT091001 to evaluate visual outcomes and safety following retreatment.